Brivudin

Definition
This section has been translated automatically.

Substance from the group of virustatics.

Half-life
This section has been translated automatically.

12–15 h

You might also be interested in

Dermatology

Trichophyton violaceum

Sabouraud and Bodin, 1902

Advertisment

Indication
This section has been translated automatically.

Infections with varicella zoster in immunocompetent adults. Efficacy in children has not been proven.

Limited indication
This section has been translated automatically.

Restricted kidney function, pregnancy, lactation.

Dosage and method of use
This section has been translated automatically.

Adults: 125 mg p.o. once/day for 7 days.

Undesirable effects
This section has been translated automatically.

Nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, proteinuria, glucosuria, creatinine and transaminase increase, leukopenia and thrombopenia, loss of appetite.

Interactions
This section has been translated automatically.

Increase in toxicity of fluorouracil and tegafur. Also no application of 5-FU topically (e.g. for the treatment of actinic keratosis).

Contraindication
This section has been translated automatically.

Patients with cytostatic therapy and antifungal therapy with flucytosine, also with topical application). The interaction with 5-fluoropyrimidines can be fatal!!!

Preparations
This section has been translated automatically.

Zostex

Note(s)
This section has been translated automatically.

The rate of post-zosteric neuralgia should be reduced by the active substance.

Literature
This section has been translated automatically.

Dworkin RH et al (2007) Recommendations for the management of herpes zoster. Clin Infect Dis 44: 1-26
Drug Commission of the German Medical Association: (2006) "UAW - learning from mistakes": potentially fatal interaction between brivudine (Zostex®) and 5-fluoropyrimidines. Dtsch Arztebl 103: A 1922-1923
WHO Pharmaceuticals Newsletter (2018) Brivudine and 5-fluorouracil - Persistence of a fatal drug-drug interaction. WHO Pharmaceuticals Newsletter 6: 20-24
https://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2019-11.html
https://www.aerzteblatt-sachsen-anhalt.de/ausgabe/arzneimittelkommission/3103-rote-hand-brief-zu-brivudin-potenziell-toedliche-toxizitaet-von-fluoropyrimidinen-bei-der-anwendung-kurz-vor-gleichzeitig-mit-oder-innerhalb-von-vier-wochen-nach-ende-der-behandlung-mit-brivudin.html